1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

作者：Y. Y. Janjigian, Akihito Kawazoe, Yikui Bai, Jiayue Xu, Sara Lonardi, J-P. Metges, P.E. Yanez Weber, Lucjan Wyrwicz, Lin Shen, Y.V. Ostapenko, Muammer Bilici, Hyun Cheol Chung, K. Shitara, Mauricio Mahave, E. Van Cutsem, Josep Tabernero, Lei Xu, Kanu Sharan, Pooja Bhagia, Sun Young Rha · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.1466 · 被引用次数：41 · 研究领域：Cancer Immunotherapy and Biomarkers、Radiopharmaceutical Chemistry and Applications、HER2/EGFR in Cancer Research